Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system

Author(s)

de Queiroz, Nina Mari G. P. ^[1] ; Marinho, Fabio V. ^[1] ; Chagas, Marcelo A. ^[1] ; Leite, Luciana C. C. ^[2] ; Homan, E. Jane ^[3] ; de Magalhaes, Mariana T. Q. ^[1] ; Oliveira, Sergio C. ^{[1, 4]}

Affiliation

^[1] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG - Brazil

^[2] Inst Butantan, Lab Desenvolvimento Vacinas, Sao Paulo, SP - Brazil

^[3] IoGenetics LLC, Madison, WI - USA

^[4] CNPq MCT, Inst Nacl Ciencia & Tecnol Doencas Trop INCT DT, Salvador, BA - Brazil

• Document type: Review article
• Source: Microbes and Infection; v. 22, n. 10, p. 515-524, NOV-DEC 2020.
• Web of Science Citations: 0

Abstract

This article discusses standard and new disruptive strategies in the race to develop an anti-COVID-19 vaccine. We also included new bioinformatic data from our group mapping immunodominant epitopes and structural analysis of the spike protein. Another innovative approach reviewed here is the use of BCG vaccine as priming strategy and/or delivery system expressing SARS-CoV-2 antigens. (C) 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. (AU)

• FAPESP's process: 17/24832-6 - Development of vaccines based on recombinant BCG: Tuberculosis, Pertussis, Pneumococcus and Schistosoma
• Grantee: Luciana Cezar de Cerqueira Leite
• Support Opportunities: Research Projects - Thematic Grants